Fluzoparib shows promising activity against BRCA-mutant relapsed ovarian cancer

The poly(ADP-ribose) polymerase (PARP) inhibitor fluzoparib appears to work in the treatment of patients with germline BRCA1/2-mutated, platinum-sensitive relapsed ovarian cancer, with an acceptable safety profile, as shown in a phase II trial.

A total of 113 patients received at least one dose of fluzoparib, administered orally at 150 mg twice daily. All of them had previously received two to four lines of platinum-based chemotherapy.

Over a median follow-up of 15.9 months (interquartile range, 13.5–18.5), objective response rates were 69.9 percent (95 percent confidence interval [CI], 60.6–78.2) as assessed by the independent review committee (IRC) and 70.8 percent (95 percent CI, 61.5–79.0) as assessed by the investigators. The objective response rates did not significantly differ across all prespecified subgroups.

Meanwhile, the median progression-free survival was 12.0 months (95 percent CI, 9.3–13.9) and 10.3 months (95 percent CI, 9.2–12.0) according to IRC and the investigators, respectively. The survival rate at 12 months was 93.7 percent (95 percent CI, 87.2–96.9).

In terms of safety, 72 patients (63.7 percent) developed grade ≥3 adverse events, the most common of which was anaemia or decreased haemoglobin. Adverse events resulted in treatment interruption, dose reduction, and discontinuation in 39.8 percent, 34.5 percent, and 0.9 percent of patients, respectively. One treatment-related death occurred.